Welcome!

News Feed Item

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

LONDON, Aug. 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312349/Trigeminal-Neuralgia-Global-Clinical-Trials-Review-H2-2014.html

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Trigeminal Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Trigeminal Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Trigeminal Neuralgia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Trigeminal Neuralgia 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Clinical Trials by G7 Countries: Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Unaccomplished Trials of Trigeminal Neuralgia 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Trigeminal Neuralgia Therapeutics Clinical Trials 26
Prominent Drugs 27
Latest Clinical Trials News on Trigeminal Neuralgia 28
Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study 28
Clinical Trial Profiles 29
Clinical Trial Overview of Top Companies 29
Merz Pharma GmbH & Co. KgaA 29
Clinical Trial Overview of Merz Pharma GmbH & Co. KgaA 29
Desitin Arzneimittel GmbH 30
Clinical Trial Overview of Desitin Arzneimittel GmbH 30
Convergence Pharmaceuticals Ltd. 31
Clinical Trial Overview of Convergence Pharmaceuticals Ltd. 31
Allodynic Therapeutics, LLC 32
Clinical Trial Overview of Allodynic Therapeutics, LLC 32
Clinical Trial Overview of Top Institutes / Government 33
Stanford University 33
Clinical Trial Overview of Stanford University 33
Thomas Jefferson University 34
Clinical Trial Overview of Thomas Jefferson University 34
University Health Network 35
Clinical Trial Overview of University Health Network 35
National Institute of Dental and Craniofacial Research 36
Clinical Trial Overview of National Institute of Dental and Craniofacial Research 36
Shahid Sadoughi University of Medical Sciences and Health Services 37
Clinical Trial Overview of Shahid Sadoughi University of Medical Sciences and Health Services 37
FDA Office of Orphan Products Development 38
Clinical Trial Overview of FDA Office of Orphan Products Development 38
University of Malaya 39
Clinical Trial Overview of University of Malaya 39
Riken Advanced Science Institute 40
Clinical Trial Overview of Riken Advanced Science Institute 40
University College London 41
Clinical Trial Overview of University College London 41
Capital Medical University 42
Clinical Trial Overview of Capital Medical University 42
Five Key Clinical Profiles 43
Appendix 58
Abbreviations 58
Definitions 58
Research Methodology 59
Secondary Research 59
About GlobalData 60
Contact Us 60
Disclaimer 60
Source 60

List of Tables
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Region, 2014* 7
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Trigeminal Neuralgia Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Trigeminal Neuralgia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Trigeminal Neuralgia Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Trigeminal Neuralgia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Phase, 2014* 18
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 19
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 21
Trigeminal Neuralgia Therapeutics, Global, Withdrawn Clinical Trials, 2014* 22
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Trigeminal Neuralgia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 24
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Merz Pharma GmbH & Co. KgaA, 2014* 29
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Desitin Arzneimittel GmbH, 2014* 30
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Convergence Pharmaceuticals Ltd., 2014* 31
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Allodynic Therapeutics, LLC, 2014* 32
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 33
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Thomas Jefferson University, 2014* 34
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University Health Network, 2014* 35
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Dental and Craniofacial Research, 2014* 36
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Shahid Sadoughi University of Medical Sciences and Health Services, 2014* 37
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by FDA Office of Orphan Products Development, 2014* 38
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Malaya, 2014* 39
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Riken Advanced Science Institute, 2014* 40
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University College London, 2014* 41
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Capital Medical University, 2014* 42

List of Figures
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Trigeminal Neuralgia Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Trigeminal Neuralgia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Trigeminal Neuralgia Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Phase (%), 2014* 18
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 19
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Trigeminal Neuralgia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 24
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
GlobalData Methodology 59


Read the full report:
Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312349/Trigeminal-Neuralgia-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
My team embarked on building a data lake for our sales and marketing data to better understand customer journeys. This required building a hybrid data pipeline to connect our cloud CRM with the new Hadoop Data Lake. One challenge is that IT was not in a position to provide support until we proved value and marketing did not have the experience, so we embarked on the journey ourselves within the product marketing team for our line of business within Progress. In his session at @BigDataExpo, Sum...
Virtualization over the past years has become a key strategy for IT to acquire multi-tenancy, increase utilization, develop elasticity and improve security. And virtual machines (VMs) are quickly becoming a main vehicle for developing and deploying applications. The introduction of containers seems to be bringing another and perhaps overlapped solution for achieving the same above-mentioned benefits. Are a container and a virtual machine fundamentally the same or different? And how? Is one techn...
The modern software development landscape consists of best practices and tools that allow teams to deliver software in a near-continuous manner. By adopting a culture of automation, measurement and sharing, the time to ship code has been greatly reduced, allowing for shorter release cycles and quicker feedback from customers and users. Still, with all of these tools and methods, how can teams stay on top of what is taking place across their infrastructure and codebase? Hopping between services a...
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex softw...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The int...
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, discussed how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a practic...
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
The cloud competition for database hosts is fierce. How do you evaluate a cloud provider for your database platform? In his session at 18th Cloud Expo, Chris Presley, a Solutions Architect at Pythian, gave users a checklist of considerations when choosing a provider. Chris Presley is a Solutions Architect at Pythian. He loves order – making him a premier Microsoft SQL Server expert. Not only has he programmed and administered SQL Server, but he has also shared his expertise and passion with budd...
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Apache Hadoop is emerging as a distributed platform for handling large and fast incoming streams of data. Predictive maintenance, supply chain optimization, and Internet-of-Things analysis are examples where Hadoop provides the scalable storage, processing, and analytics platform to gain meaningful insights from granular data that is typically only valuable from a large-scale, aggregate view. One architecture useful for capturing and analyzing streaming data is the Lambda Architecture, represent...
SYS-CON Events announced today that Ocean9will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Ocean9 provides cloud services for Backup, Disaster Recovery (DRaaS) and instant Innovation, and redefines enterprise infrastructure with its cloud native subscription offerings for mission critical SAP workloads.
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.